ImmunoPrecise Antibodies (IPA) Company Overview

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (“IPA” or the “Company”) (NASDAQ: IPA), a leader in AI-driven antibody discovery and development, today announced the successful completion of its previously disclosed USD $8.8 million “at-the-market” equity offering program (the “ATM Program”) alongside the full conversion of its outstanding debenture with Yorkville Advisors, significantly enhancing the Company's capital structure. Strategic ATM Offering Raises USD $7.0 Million Util.

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction in diabetes treatment. These AI-designed therapeutics aim to improve upon current GLP-1 therapies, which are widely used for managing type 2 diabetes and obesity. Created using the Company's proprietary LENSai™ platform, an AI-driven system that an.

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. By combining advanced artificial intelligence with first-principles thinking, the BioStrand pipeline reimagines drug discovery, offering unmatched speed, precision, and transparency. Traditional drug discovery often builds on outdated frameworks, layering new tools onto existin.

In honor of its newest beer, brewery to celebrate “Quitter's Day” and reward drinkers who throw in the towel on their New Year's resolutions early with beer money and medals In honor of its newest beer, brewery to celebrate “Quitter's Day” and reward drinkers who throw in the towel on their New Year's resolutions early with beer money and medals

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time. “Kristin has been a valued member of our team over this past year," said Dr. Jennifer Bath, IPA's President and Chief Executive Officer. ".

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce significant insider activity, with key members of its executive team and subsidiary co-founders demonstrating confidence in the Company's strategic direction and long-term potential through substantial share purchases. Over the past week, CEO Dr. Jennifer Bath and BioStrand co-founders Dirk Va.

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q2 2025 Earnings Conference Call December 10, 2024 10:30 AM ET Company Participants Jennifer Bath - CEO Kristin Taylor - CFO Conference Call Participants Swayampakula Ramakanth - H.C.

ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05.

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts. This exclusive gathering will highlight IPA's latest advancements in AI-driven design, biologics innovation, and strategic technological developments. Highlights of TECHDAY: Prese.